…
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has a collaboration with Phylo, Inc. to deploy an agentic AI platform for biomedical research across its drug discovery workflow. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Chugai Pharmaceutical is a Japan-based research-driven biopharmaceutical company that discovers, develops and markets prescription therapeutics, with strengths in oncology and immunology and majority ownership by Roche. Long-term growth drivers include its biologics-focused R&D pipeline, collaboration with Roche for global commercialization, and an expanding portfolio of specialty medicines that may benefit from demographic aging and demand for targeted therapies.
Key risks are clinical and regulatory setbacks, patent expirations and biosimilar competition for core products, dependence on the Roche partnership and Japanese pricing pressure could reduce revenue visibility.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 598328.65M | 543034.00M | 443821.00M | 531166.00M | 419385.00M |
| Net income | 434390.72M | 387317.00M | 325472.00M | 374429.00M | 302995.00M |
| Selling general administrative | 116461.00M | 110098.00M | 112857.00M | 23611.00M | 25824.00M |
| Selling and marketing expenses | - | 110098.00M | 112580.00M | 77149.00M | 76592.00M |
| Gross profit | 895031.33M | 831202.00M | 698061.00M | 783695.00M | 661612.00M |
| Ebit | 599355.55M | 542002.00M | 439174.00M | 533309.00M | 421897.00M |
| Ebitda | 631918.94M | 573667.00M | 470914.00M | 531227.00M | 419433.00M |
| Depreciation and amortization | 32563.39M | 31665.00M | 31740.00M | -2082.00M | -2464.00M |
| Operating income | 590707.01M | 542002.00M | 439174.00M | 533309.00M | 421897.00M |
| Other operating expenses | 668331.69M | 628609.00M | 672193.00M | 726637.00M | 577862.00M |
| Interest expense | 1026.89M | 1027.00M | 27.00M | 61.00M | 48.00M |
| Tax provision | 163794.00M | 155717.00M | 133602.00M | 156737.00M | 116390.00M |
| Interest income | - | 5.00M | - | - | - |
| Net interest income | -1026.00M | 1032.00M | 3007.00M | -9.00M | 28.00M |
| Income tax expense | 163936.93M | 155717.00M | 118349.00M | 156737.00M | 116390.00M |
| Total revenue | 1259038.69M | 1170611.00M | 1111367.00M | 1259946.00M | 999759.00M |
| Total operating expenses | 304324.33M | 289200.00M | 258887.00M | 250386.00M | 239715.00M |
| Cost of revenue | 364007.36M | 339409.00M | 413306.00M | 476251.00M | 338147.00M |
| Total other income expense net | 7621.65M | 1032.00M | 4647.00M | -2143.00M | -2512.00M |
| Net income from continuing ops | 434012.00M | 387317.00M | 336745.00M | 374429.00M | 302995.00M |
| Net income applicable to common shares | - | - | - | 374429.00M | 302995.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 2470749.13M | 2208373.00M | 1932547.00M | 1869758.00M | 1538694.00M |
| Intangible assets | 54586.59M | 17868.00M | 19860.00M | 25141.00M | 21974.00M |
| Other current assets | 41137.87M | 35375.00M | 35072.00M | 26941.00M | 26844.00M |
| Total liab | 443247.45M | 306874.00M | 306967.00M | 445371.00M | 350677.00M |
| Total stockholder equity | 2027499.68M | 1901499.00M | 1625580.00M | 1424387.00M | 1188017.00M |
| Other current liab | 276297.89M | 218639.00M | 134951.00M | 213895.00M | 175156.00M |
| Common stock | 73265.88M | 73202.00M | 73202.00M | 73202.00M | 73202.00M |
| Retained earnings | 1891691.27M | 1746934.00M | 1488738.00M | 1293352.00M | 1054050.00M |
| Other liab | - | - | - | 21641.00M | 13765.00M |
| Other assets | - | - | - | 121429.00M | 56289.00M |
| Cash | 426974.26M | 540202.00M | 458674.00M | 222169.00M | 267753.00M |
| Total current liabilities | 411435.71M | 290357.00M | 288217.00M | 423730.00M | 327422.00M |
| Current deferred revenue | - | - | 31.00M | - | - |
| Net debt | -401241.82M | -529305.00M | -458674.00M | -222169.00M | -267753.00M |
| Short term debt | 7779.78M | 6365.00M | 6975.00M | - | - |
| Short long term debt total | 25732.44M | 10897.00M | 13455.00M | - | - |
| Other stockholder equity | 70575.53M | 69896.00M | 142557.00M | -10973.00M | -7458.00M |
| Property plant equipment | - | - | - | 386651.00M | 352107.00M |
| Total current assets | 1742277.01M | 1606043.00M | 1366426.00M | 1336537.00M | 1063661.00M |
| Net tangible assets | - | - | - | 1399246.00M | 1166043.00M |
| Short term investments | 553576.64M | 456143.00M | 280308.00M | 280938.00M | 204217.00M |
| Net receivables | 443498.66M | 334256.00M | 318892.00M | 514283.00M | 356009.00M |
| Inventory | 277089.58M | 240067.00M | 273480.00M | 292206.00M | 208838.00M |
| Accounts payable | 127358.04M | 65353.00M | 112468.00M | 209835.00M | 152266.00M |
| Accumulated other comprehensive income | -8033.00M | 11467.00M | -5715.00M | - | - |
| Non currrent assets other | 97145.70M | 69835.00M | 64474.00M | 335286.00M | 246489.00M |
| Non current assets total | 728472.12M | 602330.00M | 566121.00M | 533221.00M | 475033.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -100804.00M | -227365.00M | -65479.00M | -145994.00M | -47236.00M |
| Change to liabilities | - | - | - | 0.00M | 0.00M |
| Total cashflows from investing activities | -205051.77M | -227365.00M | -37290.00M | -145994.00M | -118927.00M |
| Net borrowings | - | - | - | -7599.00M | -7599.00M |
| Total cash from financing activities | -307725.29M | -141006.00M | -139331.00M | -145641.00M | -107408.00M |
| Change to operating activities | - | - | - | -183311.00M | 43523.00M |
| Net income | 434390.72M | 589546.00M | 325472.00M | 575875.00M | 470367.00M |
| Change in cash | -111919.76M | 81528.00M | 236505.00M | -45584.00M | 55420.00M |
| Begin period cash flow | 538894.02M | 458674.00M | 222169.00M | 267753.00M | 212333.00M |
| End period cash flow | 426974.26M | 540202.00M | 458674.00M | 222169.00M | 267753.00M |
| Total cash from operating activities | 389790.84M | 447600.00M | 409925.00M | 244112.00M | 279626.00M |
| Issuance of capital stock | 142.00M | 168.00M | 179.00M | 241.00M | 322.00M |
| Depreciation | 32563.39M | - | 31740.00M | 31434.00M | 30868.00M |
| Other cashflows from investing activities | 29.03M | 1099.00M | 33679.00M | 280.00M | 133.00M |
| Dividends paid | 299680.28M | 133249.00M | 131594.00M | -138220.00M | -98644.00M |
| Change to inventory | - | - | - | - | -25500.00M |
| Change to account receivables | - | - | - | - | -85200.00M |
| Sale purchase of stock | -6.00M | -10.00M | -5.00M | -5.00M | -8.00M |
| Other cashflows from financing activities | -8181.13M | -7915.00M | -7949.00M | -7657.00M | -9078.00M |
| Change to netincome | - | - | - | 21560.00M | -97760.00M |
| Capital expenditures | 76339.56M | 54899.00M | 74258.00M | 71239.00M | 72866.00M |
| Change in working capital | -79720.50M | -28843.00M | 130634.00M | -183311.00M | -83122.00M |
| Other non cash items | 2557.23M | -113103.00M | -46181.00M | -148452.00M | -107619.00M |
| Free cash flow | 313451.28M | 392701.00M | 335667.00M | 172873.00M | 206760.00M |
Sector: Healthcare Industry: Drug Manufacturers - General
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CHGCF Chugai Pharmaceutical Co. Ltd |
- -% |
44.52 | 23.01 | 18.42 | 0.05 | 5.34 | 7.14 | 14.64 |
| LLY Eli Lilly and Company |
-0.08 0.01% |
1351.12 | 38.16 | 24.15 | 12.72 | 29.95 | 13.31 | 25.43 |
| JNJ Johnson & Johnson |
-5.68 2.08% |
267.02 | 30.96 | 20.79 | 6.58 | 7.55 | 6.84 | 19.73 |
| ABBV AbbVie Inc |
0.10 0.04% |
283.54 | 74.10 | 16.21 | 7.22 | 50.46 | 8.18 | 27.04 |
| RHHVF Roche Holding AG Participation |
- -% |
480.00 | 24.16 | 16.53 | 5.71 | 8.88 | 4.94 | 14.76 |
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has a collaboration with Phylo, Inc. to deploy an agentic AI platform for biomedical research across its drug discovery workflow. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.
| Name | Title | Year Born |
|---|---|---|
| Dr. Osamu Okuda | Pres, CEO & Representative Director | 1963 |
| Mr. Toshiaki Itagaki | Head of Fin. Supervisory Division, CFO, Exec. VP & Director | 1960 |
| Toshiya Sasai | Exec. of Investor Relations Group & Corp. Communications Department | NA |
| Masahiko Uchida | Gen. Mang. of Corp. Communications Department | NA |
| Mr. Shinji Hidaka | Exec. VP and Head of Marketing & Sales Division | NA |
| Mr. Tsunanori Sato | VP and GM of Marketing & Sales Division | NA |
| Mr. Yoshiyuki Yano | Exec. VP & Head of HR Management Department | NA |
| Mr. Junichi Ebihara | Exec. VP | NA |
| Dr. Yoshiaki Ohashi | SVP & Full-time Audit Supervisory Board Member | 1960 |
| Mr. Tetsuya Yamaguchi | Exec. VP and Head of Project & Lifecycle Management Unit | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.